Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot Password? Reset your password

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login (Shibboleth)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Table of Contents
Vol. 16, No. 1, 2008
Issue release date: December 2007
Section title: Paper
Free Access
Neurosignals 2008;16:11–18

Biomarkers for Early Detection of Alzheimer Pathology

Clark C.M.a, d-f · Davatzikos C.b · Borthakur A.b · Newberg A.b · Leight S.c, g · Lee V.M.-Y.c, f, g · Trojanowski J.Q.c-g
Departments of aNeurology, bRadiology and cPathology and Laboratory Medicine, dCenter of Excellence for Research on Neurodegenerative Diseases, eAlzheimer Disease Center, fInstitute on Aging, and gCenter for Neurodegenerative Disease Research, University of Pennsylvania, Philadelphia, Pa., USA
email Corresponding Author

Chris M. Clark, MD

Penn – Ralston Center, University of Pennsylvania

3615 Chestnut Street

Philadelphia, PA 19104 (USA)

Tel. +1 215 662 7810, Fax +1 215 662 7812, E-Mail chris.clark@uphs.upenn.edu

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


The increasing prevalence of Alzheimer’s disease and the devastating consequences of late-life dementia motivates the drive to develop diagnostic biomarkers to reliably identify the pathology associated with this disorder. Strategies to accomplish this include the detection of altered levels of tau and amyloid in cerebrospinal fluid, the use of structural MRI to identify disease-specific patterns of regional atrophy and MRI T1ρ to detect disease-related macromolecular protein aggregation, and the direct imaging of amyloid deposits using positron emission tomography and single photon emission computerized tomography. Success will facilitate the ability to reliably diagnose Alzheimer’s disease while the symptoms of brain failure are mild and may provide objective measures of disease-modifying treatment efficacy.

© 2008 S. Karger AG, Basel

Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: December 05, 2007
Issue release date: December 2007

Number of Print Pages: 8
Number of Figures: 4
Number of Tables: 2

ISSN: 1424-862X (Print)
eISSN: 1424-8638 (Online)

For additional information: http://www.karger.com/NSG

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.